A stabilized GHRH analog that is FDA-approved (as Egrifta) to reduce excess visceral adipose tissue in HIV-associated lipodystrophy — one of the few peptides in this index with an approved human indication.
Mechanism under study
Binds the GHRH receptor to increase growth hormone and IGF-1, with clinical study emphasis on reduction of visceral (deep abdominal) fat.
Research-reported dosing
Its approved clinical regimen is ~2 mg subcutaneously once daily. This is a labeled human indication, distinct from most entries here.
Based on a standard 5 mg vial: with 2 mL bacteriostatic water = 2,500 mcg/mL (2.5 mg/mL); 1 unit ≈ 25 mcg.
Open this mix in the calculator →Source research-grade Tesamorelin ↗Dosing figures describe how this compound appears in the research literature and research-community references. They are not a recommendation for human use.
Tesamorelin FAQ
What is Tesamorelin?
A stabilized GHRH analog that is FDA-approved (as Egrifta) to reduce excess visceral adipose tissue in HIV-associated lipodystrophy — one of the few peptides in this index with an approved human indication.
What is the half-life of Tesamorelin?
Approximately 26–38 minutes.
What is the research-reported dosing for Tesamorelin?
Its approved clinical regimen is ~2 mg subcutaneously once daily. This is a labeled human indication, distinct from most entries here.
How is Tesamorelin reconstituted?
Based on a standard 5 mg vial: with 2 mL bacteriostatic water = 2,500 mcg/mL (2.5 mg/mL); 1 unit ≈ 25 mcg.
Is Tesamorelin FDA-approved?
Tesamorelin has an approved status in at least one context — see the overview above for the specific brand, region, and indication. Research-grade material sold separately is for laboratory use only.
References
Guides featuring Tesamorelin
Related peptides
Sermorelin
Growth-hormone-releasing hormone (GHRH) analog
A GHRH (1-29) analog — the shortest fully active fragment of GHRH — historically used clinically as a diagnostic agent and studied for supporting endogenous growth-hormone output.
CJC-1295
Growth-hormone-releasing hormone (GHRH) analog
A synthetic GHRH analog studied for stimulating growth-hormone release. Exists in a short-acting 'no-DAC' form (modified GRF 1-29) and a long-acting 'DAC' form.
Semaglutide
GLP-1 receptor agonist
A long-acting GLP-1 receptor agonist, FDA-approved for type-2 diabetes and chronic weight management under brand names Ozempic, Wegovy, and Rybelsus. One of the most-studied incretin peptides.